Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claude-Alain Maurage

Showing results (101-110 of 141) with videos related to

Pageof 15
Sort By:
Clinical Endocrinology|April 26, 2022
Efficacy of lanreotide 120 mg primary therapy on tumour shrinkage and ophthalmologic symptoms in acromegaly after 1 monthHamza Benderradji, Elise Vernotte, Gustave Soto Ares, et al.
Brain Pathology (Zurich, Switzerland)|October 5, 2017
Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular featuresFranck Bielle, Anna-Luisa Di Stefano, David Meyronet, et al.
Acta Neuropathologica Communications|July 21, 2016
Reduced Tau protein expression is associated with frontotemporal degeneration with progranulin mutationAnthony Papegaey, Sabiha Eddarkaoui, Vincent Deramecourt, et al.
Small (Weinheim an Der Bergstrasse, Germany)|September 29, 2025
Novel Diffuse Midline Glioma-on-Chip Recapitulating Tumor Biophysical Microenvironment to Assess the Heterogeneity of Response to TherapiesLisa Terrassoux, Calypso Hazard, Agathe Laratte, et al.
Neuro-Oncology|December 14, 2019
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomasRomain Appay, Caroline Dehais, Claude-Alain Maurage, et al.
European Journal of Cancer (Oxford, England : 1990)|December 30, 2023
Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trialEmilie Le Rhun, Thierry Gorlia, Jörg Felsberg, et al.
Therapie|December 15, 2010
[Molecular actors in Alzheimer's disease: which diagnostic and therapeutic consequences?]Luc Buée, David Blum, Stéphanie Bombois, et al.
Acta Neuropathologica Communications|January 16, 2023
Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusionAlice Métais, Arnault Tauziède-Espariat, Jeremy Garcia, et al.
The American Journal of Surgical Pathology|April 2, 2015
Distinctive Patterns of Transthyretin Amyloid in Salivary Tissue: A Clinicopathologic Study of 92 Patients With Amyloid-containing Minor Salivary Gland BiopsiesMarie-Pierre Jamet, Viviane Gnemmi, Éric Hachulla, et al.
Neuromuscular Disorders : NMD|April 15, 2009
Clinical outcome in 19 French and Spanish patients with valosin-containing protein myopathy associated with Paget's disease of bone and frontotemporal dementiaTanya Stojkovic, El Hadi Hammouda, Pascale Richard, et al.
Pageof 15

Showing results (101-110 of 141) with videos related to

Sort By:
Pageof 15
Clinical Endocrinology|April 26, 2022
Efficacy of lanreotide 120 mg primary therapy on tumour shrinkage and ophthalmologic symptoms in acromegaly after 1 monthHamza Benderradji, Elise Vernotte, Gustave Soto Ares, et al.
Brain Pathology (Zurich, Switzerland)|October 5, 2017
Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular featuresFranck Bielle, Anna-Luisa Di Stefano, David Meyronet, et al.
Acta Neuropathologica Communications|July 21, 2016
Reduced Tau protein expression is associated with frontotemporal degeneration with progranulin mutationAnthony Papegaey, Sabiha Eddarkaoui, Vincent Deramecourt, et al.
Small (Weinheim an Der Bergstrasse, Germany)|September 29, 2025
Novel Diffuse Midline Glioma-on-Chip Recapitulating Tumor Biophysical Microenvironment to Assess the Heterogeneity of Response to TherapiesLisa Terrassoux, Calypso Hazard, Agathe Laratte, et al.
Neuro-Oncology|December 14, 2019
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomasRomain Appay, Caroline Dehais, Claude-Alain Maurage, et al.
European Journal of Cancer (Oxford, England : 1990)|December 30, 2023
Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trialEmilie Le Rhun, Thierry Gorlia, Jörg Felsberg, et al.
Therapie|December 15, 2010
[Molecular actors in Alzheimer's disease: which diagnostic and therapeutic consequences?]Luc Buée, David Blum, Stéphanie Bombois, et al.
Acta Neuropathologica Communications|January 16, 2023
Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusionAlice Métais, Arnault Tauziède-Espariat, Jeremy Garcia, et al.
The American Journal of Surgical Pathology|April 2, 2015
Distinctive Patterns of Transthyretin Amyloid in Salivary Tissue: A Clinicopathologic Study of 92 Patients With Amyloid-containing Minor Salivary Gland BiopsiesMarie-Pierre Jamet, Viviane Gnemmi, Éric Hachulla, et al.
Neuromuscular Disorders : NMD|April 15, 2009
Clinical outcome in 19 French and Spanish patients with valosin-containing protein myopathy associated with Paget's disease of bone and frontotemporal dementiaTanya Stojkovic, El Hadi Hammouda, Pascale Richard, et al.
Pageof 15